MGB Biopharma Limited   Report issue

For profit Phase 2
Founded: Snodland United Kingdom (2009)

Organization Overview

First Clinical Trial
2015
NCT02518607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

MGB Biopharma Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

mgb-bp-3 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1